Reduced Anticoagulation Targets in ECLS (RATE)

• Status: Recruiting
• Trial end date: 2024-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the RATE-trial is to study if reduced anticoagulation targets during ECLS diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Center Groningen
• Collaborators: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Erasmus Medical Center; Isala; Leiden University Medical Center; OLVG; Radboud University; St. Antonius Hospital; ZonMw: The Netherlands Organisation for Health Research and Development
• Treatments: Calcium heparin; Enoxaparin; Heparin; Nadroparin

Criteria

Inclusion Criteria:

• ECMO treatment during the study period in one of the participating centers

• Age above 18 years

• Written informed consent

Exclusion Criteria:

• Patients in whom the ECMO is only used to bridge a procedure

• Vital indication for robust anticoagulation (e.g. mechanic valve, pulmonary embolism)

• History of heparin induced thrombocytopenia